- Meibomian Gland Dysfunction Associated with Bortezomib in a Multiple Myeloma Patient
-
Yoon DE, Jun RM, Han KE
- KMID: 2528331
- J Korean Ophthalmol Soc.
- 2022 Apr;63(4):389-395.
- doi: 10.3341/jkos.2022.63.4.389
Purpose: This study reports a case of meibomian gland dysfunction associated with bortezomib, which is a treatment of choice for multiple myeloma. Case summary: A 59‐year‐old female patient presented to our... -
- CITED
-
- Close
- SHARE
-
- Close
- Outcomes of bortezomib combination chemotherapies in autologous stem cell transplantation-ineligible patients with AL amyloidosis
-
Hur JY, Yoon SE, Kim D, Choi Jo, Min JH, Kim BJ, Kim JS, Lee JE, Choi JY, Jeon ES, Kim SJ, Kim K
- KMID: 2524086
- Blood Res.
- 2021 Dec;56(4):266-278.
- doi: 10.5045/br.2021.2021121
Background Treatment protocols for light chain (AL) amyloidosis have been derived from myeloma treatment. Bortezomib is a key drug used for the treatment of myeloma and AL amyloidosis. We retrospectively investigated... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Sweet Syndrome Induced by Bortezomib Rechallenge
-
Jeong SMG, Kwon CI, Kim CY
- KMID: 2516144
- Korean J Dermatol.
- 2021 May;59(4):299-302.
Sweet syndrome is characterized by fever, tender, erythematous skin lesions, neutrophilia, high levels of serum inflammatory markers, and diffuse mature neutrophil infiltration typically localized to the upper dermis. Various drugs... -
- CITED
-
- Close
- SHARE
-
- Close
- Acute antibody-mediated rejection limited to medullary lesions in following ABO-incompatible living donor kidney transplantation
-
Kim AY, Cho KH, Park JW, Do JY, Han MH, Kim YJ, Kang SH
- KMID: 2514409
- Korean J Transplant.
- 2021 Mar;35(1):53-58.
- doi: 10.4285/kjt.20.0047
Anatomical differences between the renal cortex and medulla may influence inflammatory responses. Owing to the difficulty in diagnosing rejections from the medulla, rejection is usually diagnosed through the cortex. However,... -
- CITED
-
- Close
- SHARE
-
- Close
- Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
-
Lee SR, Choi H, Lee BH, Kang KW, Yu ES, Kim DS, Park Y, Choi CW, Kim BS, Sung HJ
- KMID: 2463492
- Korean J Intern Med.
- 2019 Nov;34(6):1333-1346.
- doi: 10.3904/kjim.2018.144
BACKGROUND/AIMS: Bortezomib plus melphalan-prednisone (VMP) is a standard treatment for multiple myeloma, particularly for patients who are ineligible for high-dose therapy. However, early discontinuation or treatment modification is often needed... -
- CITED
-
- Close
- SHARE
-
- Close
- Bortezomib Treatment for Refractory Antibody-Mediated Rejection Superimposed with BK Virus-Associated Nephropathy during the Progression of Recurrent C3 Glomerulonephritis
-
Do W, Lee JH, Kim KJ, Han MH, Jung HY, Choi JY, Park SH, Kim YL, Kim CD, Cho JH, Yang Y, Kim M, Hwang I, Kim KY, Yim T, Kim YJ
- KMID: 2421281
- J Korean Soc Transplant.
- 2018 Sep;32(3):57-62.
- doi: 10.4285/jkstn.2018.32.3.57
A 38-year-old man, who underwent a second kidney transplantation (KT), was admitted because of antibody-mediated rejection (AMR) complicated by BK virus-associated nephropathy (BKVAN). He was placed on hemodialysis at the... -
- CITED
-
- Close
- SHARE
-
- Close
- The Effect of Bortezomib on the Management of Immediate Postoperative Refractory Antibody-Mediated Rejection after Kidney Transplantation
-
Kim SJ, Jun KW, Hwang JK, Chung BH, Yang CW, Moon IS, Kim JI, Kim MH
- KMID: 2421280
- J Korean Soc Transplant.
- 2018 Sep;32(3):49-56.
- doi: 10.4285/jkstn.2018.32.3.49
BACKGROUND: Bortezomib has been used to treat antibody-mediated rejection (AMR) that usually develops after kidney transplantation (KT). Although it has been used in various clinical situations, it is difficult to... -
- CITED
-
- Close
- SHARE
-
- Close
- Inhibition of the 26S and 20S Proteasomes by the Site-specific Inhibitors
-
Woo KM
- KMID: 2437766
- Soonchunhyang Med Sci.
- 2018 Jun;24(1):47-54.
- doi: 10.0000/sms.2018.24.1.47
OBJECTIVE: The study was performed to establish the purification processes of both 26S and 20S proteasomes, also to investigate the inhibitory properties and patterns of two different proteasome inhibitors on... -
- CITED
-
- Close
- SHARE
-
- Close
- Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen
-
Cho HJ, Seo SK, Baek DW, Park SW, Lee YJ, Sohn SK, Lee HS, Lee WS, Lee JH, Kim SH, Moon JH
- KMID: 2415737
- Yeungnam Univ J Med.
- 2018 Jun;35(1):76-83.
- doi: 10.12701/yujm.2018.35.1.76
BACKGROUND: Elderly patients with multiple myeloma (MM) are vulnerable to adverse events (AEs). This study evaluated adherence to chemotherapy and treatment outcomes in elderly patients treated with a frontline bortezomib... -
- CITED
-
- Close
- SHARE
-
- Close
- Bortezomib-induced Histiocytoid Sweet Syndrome
-
Oh YJ, Lew BL, Sim WY
- KMID: 2359680
- Korean J Dermatol.
- 2016 Nov;54(9):739-743.
Sweet syndrome is an acute febrile neutrophilic dermatosis predominantly characterized by fever, an elevated neutrophil count, and erythematous skin lesions comprising plaques and nodules that mainly appear on the upper... -
- CITED
-
- Close
- SHARE
-
- Close
- Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients
-
Lee SS, Jung SH, Ahn JS, Kim YK, Cho MS, Jung SY, Lee JJ, Kim HJ, Yang DH
- KMID: 2373738
- J Korean Med Sci.
- 2016 Jul;31(7):1160-1163.
- doi: 10.3346/jkms.2016.31.7.1160
Peripheral T cell lymphoma (PTCL) is a heterogeneous group of aggressive lymphomas with poor prognosis. Elderly (age ≥ 65years) patients generally have impaired bone marrow function, altered drug metabolism, comorbidities,... -
- CITED
-
- Close
- SHARE
-
- Close
- Pretreatment Lymphopenia, Poor Performance Status, and Early Courses of Therapy Are Risk Factors for Severe Bacterial Infection in Patients with Multiple Myeloma during Treatment with Bortezomib-based Regimens
-
Hyun SY, Han SH, Kim SJ, Jang JE, Kim Y, Cho H, Lee JY, Cheong JW, Min YH, Song JW, Kim JS
- KMID: 2363688
- J Korean Med Sci.
- 2016 Apr;31(4):510-518.
- doi: 10.3346/jkms.2016.31.4.510
The aim of this study was to identify the risk factors associated with severe bacterial infection (SBI) in multiple myeloma (MM) patients during treatment with bortezomib-based regimens. A total of... -
- CITED
-
- Close
- SHARE
-
- Close
- Two Cases of Bortezomib-induced Drug Eruption Presenting as Multiple Plaques on the Trunk
-
Choe YS, Kim EJ, Na JI
- KMID: 2245828
- Korean J Dermatol.
- 2016 Jan;54(1):47-51.
Bortezomib (Velcade(R)) is proteasome inhibitor that is used as a first-line therapy for multiple myeloma. It can cause gastrointestinal, hematologic, and neuromuscular side effects, and a cutaneous reaction is one... -
- CITED
-
- Close
- SHARE
-
- Close
- The Effect of Bortezomib on Antibody-Mediated Rejection after Kidney Transplantation
-
Lee J, Kim BS, Park Y, Lee JG, Lim BJ, Jeong HJ, Kim YS, Huh KH
- KMID: 2345894
- Yonsei Med J.
- 2015 Nov;56(6):1638-1642.
- doi: 10.3349/ymj.2015.56.6.1638
PURPOSE: Recently, bortezomib has been used to treat antibody-mediated rejection (AMR) refractory to conventional treatment such as plasmapheresis, intravenous immunoglobulin, and rituximab. The authors aimed to describe their experiences when... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Acute Pancreatitis Caused by Bortezomib in a Patient with Multiple Myeloma
-
Lim JH, Hwang KB, Lim BH, Jeong YH, Sohn KC, Kim TH
- KMID: 2448488
- Korean J Pancreas Biliary Tract.
- 2015 Jul;20(3):136-139.
- doi: 10.15279/kpba.2015.20.3.136
Bortezomib is a proteasome inhibitor used for the treatment of patients with multiple myeloma. Recently, several case reports about acute pancreatitis caused by Bortezomib were published in the international literature.... -
- CITED
-
- Close
- SHARE
-
- Close
- Bortezomib inhibits the survival and proliferation of bone marrow stromal cells
-
Kim HY, Moon JY, Ryu H, Choi YS, Song IC, Lee HJ, Yun HJ, Kim S, Jo DY
- KMID: 2172772
- Blood Res.
- 2015 Jun;50(2):87-96.
- doi: 10.5045/br.2015.50.2.87
BACKGROUND: Bortezomib is widely used for the treatment of multiple myeloma. Bone marrow stromal cells (BMSCs) endow myeloma cells with survival and growth advantages. However, the influence of bortezomib on... -
- CITED
-
- Close
- SHARE
-
- Close
- Bortezomib-Based Salvage Chemotherapy in Refractory/Relapsed Multiple Myeloma Patients: A Single Center Experience in Real Clinical Practice
-
Kim DH, Lee JH, Kim SH, Oh SY, Lee S, Moon SY, Kim HJ
- KMID: 1834041
- Korean J Med.
- 2015 May;88(5):537-546.
- doi: 10.3904/kjm.2015.88.5.537
BACKGROUND/AIMS: Bortezomib-based chemotherapy has proven to be an effective salvage regimen for refractory/relapsed multiple myeloma patients in many clinical trials. However, few reports have shown the outcomes and adverse events... -
- CITED
-
- Close
- SHARE
-
- Close
- Reversible Heart Failure after Bortezomib Treatment in a Patient with Multiple Myeloma
-
Song J, Kim H, Shin S, Kim I, Oh D, Chong S
- KMID: 2269134
- Korean J Med.
- 2015 Apr;88(4):459-463.
- doi: 10.3904/kjm.2015.88.4.459
Bortezomib (Velcade(R)) came into the spotlight as a target therapy for multiple myeloma. It acts through reversible inhibition of intracellular proteasomes, which triggers apoptosis, with relative selectivity for malignant cells.... -
- CITED
-
- Close
- SHARE
-
- Close
- The Effect of Bortezomib on Expression of Inflammatory Cytokines and Survival in a Murine Sepsis Model Induced by Cecal Ligation and Puncture
-
Han SH, Kim JS, Woo JH, Jeong SJ, Shin JS, Ahn YS, Kim JM
- KMID: 2352796
- Yonsei Med J.
- 2015 Jan;56(1):112-123.
- doi: 10.3349/ymj.2015.56.1.112
PURPOSE: Although the proteasome inhibitor known as bortezomib can modulate the inflammatory process through the nuclear factor-kappa B signaling pathway, the immunomodulatory effect of pre-incubated bortezomib has not been fully... -
- CITED
-
- Close
- SHARE
-
- Close
- Use of Bortezomib as Anti-Humoral Therapy in Kidney Transplantation
-
Yang KS, Jeon H, Park Y, Jo IH, Kim JI, Moon IS, Choi BS, Park CW, Yang CW, Kim YS, Chung BH
- KMID: 1786104
- J Korean Med Sci.
- 2014 May;29(5):648-651.
- doi: 10.3346/jkms.2014.29.5.648
This study aimed to investigate the effect of bortezomib in the desensitization and treatment of acute antibody mediated rejection (AAMR) in kidney transplantation. Nine patients who received bortezomib therapy for... -
- CITED
-
- Close
- SHARE
-
- Close
